ClinicalTrials.gg
CompletedNCT01178281RESUMEUpdated Jul 17, 2019Results posted

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

A Phase 3 interventional study of Pomalidomide 0.5 mg and Placebo in Primary Myelofibrosis and MPN-associated Myelofibrosis, sponsored by Celgene. Completed at 87 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-17.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 1 of them phase 3. Primary Myelofibrosis · Bristol-Myers Squibb.

Enrollment
2nd of 10
267 · median 92
Started
2010
the only one that year
Phase 3
4 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 3, and was the 3rd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

1 of the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibrosis and severe anemia not receiving RBC-transfusions (China extension study only)

Read the detailed description

The multicenter global study was conducted in 15 countries including Australia, Austria, Belgium, Canada, China, France, Germany, Italy, Japan, the Netherlands, Russia, Spain, Sweden, the United Kingdom, and the United States. The global study enrolled participants with myeloproliferative neoplasm (MPN)-associated myelofibrosis and RBC-transfusion-dependence. Participants were randomly assigned to receive pomalidomide or placebo in a blinded fashion.

In most countries participating in the global study, RBC-transfusions are typically given for a hemoglobin level \<80-90 g/L. In China, RBC-transfusions are rarely given unless the hemoglobin level is \<60 g/L. Consequently, few Chinese with MPN-associated myelofibrosis meet RBC-transfusion-dependence criteria of the global study. A China-specific extension was developed to test the ability of pomalidomide to improve severe anemia (defined as a hemoglobin \< 80 g/L for ≥ 84 days in persons not receiving RBC-transfusions).

The China-specific extension study consisted of a single-arm, open-label study in adults with MPN-associated myelofibrosis and severe anemia not receiving RBC transfusions with the objective of describing the frequency of anemia response.

The Global (intent-to-treat [ITT] and safety) population in the main study and the China extension (ITT and safety) population are mutually exclusive.

03

Conditions studied

  • Primary Myelofibrosis
  • MPN-associated Myelofibrosis

Browse trials for

Keywords

  • Myelofibrosis
  • Post-polycythemia vera myelofibrosis
  • Post-essential thrombocythemia myelofibrosis
  • RBC-transfusion-dependence
  • Primary Myelofibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Myeloproliferative-neoplasm (MPN)-associated myelofibrosis
  • RBC-transfusion-dependence (global study):

    • Average RBC-transfusion frequency ≥ 2 units/28 days over at least the 84 days immediately prior to randomization. There must be no interval > 42 days without ≥ 1 RBC-transfusion.
    • Only RBC-transfusions given when the ≤ 90 g/L³ are scored in

determining eligibility.

  • RBC-transfusions due to bleeding are not scored in determining eligibility.
  • RBC-transfusions due to chemotherapy-induced anemia are not scored in determining eligibility.

    • Severe anemia (China-specific extension):
  • ≥ 2 hemoglobin concentrations ≤ 80 g/L for ≥ 84 days immediately before the day of enrollment.
  • No RBC-transfusion within 6 months prior to enrollment.

    • Hemoglobin ≤ 130 g/L at randomization (global study); ≤ 80 g/L at enrollment in the China-specific extension.
    • Bone marrow within 6 months (global study only).
    • Inappropriate to receive blood cell or bone marrow allotransplant, erythropoietin and androgenic steroids
    • (ECOG) performance status ≤ 2.
    • Agree to follow pregnancy precautions as required by the protocol.
    • Agree to receive counseling related to teratogenic and other risks of pomalidomide.
    • Agree not to donate blood or semen.

Exclusion criteria

Exclusion Criteria:

  • Prior blood cell or bone marrow allotransplant.
  • Use of drugs to treat MPN-associated myelofibrosis ≤ 30 days before starting study drug.
  • Treatment with erythropoietin or androgenic steroids ≤ 84 days before starting study drug.
  • Anemia due to reasons other than MPN-associated myelofibrosis.
  • Pregnant or lactating females.
  • More than 10% blasts by bone marrow examination or more than 10% blasts in blood in consecutive measurements spanning at least 8 weeks
  • Prior history of ,other than the disease being studied, unless the subject has been free of the malignancy for ≥ 5 years with the following exceptions:

    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T 1a or T 1b using TNM [tumor, nodes, ] clinical staging system)
  • (HIV) infection, active virus (HBV) or virus (HCV) infections.
  • Prior treatment with pomalidomide.
  • Allergic reaction or rash after treatment with thalidomide or lenalidomide
  • Any of the following laboratory abnormalities:

    • Neutrophils \< 0.5x10\^9 /L
    • \< 25 x 10\^9 /L
    • Estimated (kidney function) \< 30 mL/min/1.73 m²
    • (AST) and alanine transaminase (ALT) > 3.0 x (ULN)
    • Total ≥ 4 x ULN;
  • Uncontrolled hyperthyroidism or hypothyroidism.
  • Deep venous thrombosis (DVT) or pulmonary embolus (PE) \< 6 months before starting study drug
  • Clinically-important heart disease within the past 6 months
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Pomalidomide 0.5 mg

    Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression. Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied.

    Drug: Pomalidomide 0.5 mg

  • Placebo comparator
    Placebo

    Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression. Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied.

    Drug: Placebo

  • Experimental
    China Extension: Pomalidomide 0.5 mg

    Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion. Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied.

    Drug: Pomalidomide

Interventions

  • Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.

    Also known as: CC-4047; Pomalyst; Imnovid

  • DrugPlacebo

    Placebo Comparator to active drug; Placebo capsule taken by mouth once daily

  • Pomalidomide 0.5 mg capsule taken by mouth once daily.

    Also known as: CC-4047, Pomalyst, Imnovid

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved RBC-Transfusion Independence

    RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval.

    Time frame: 168 days

  2. China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days

    A response in the China extension study was defined as an increase in hemoglobin ≥ 15 g/L above baseline value (in the absence of RBC transfusion) for ≥ 84 consecutive days.

    Time frame: From the first dose of study drug until treatment discontinuation; median treatment duration was 24.0 weeks.

Secondary outcomes

  1. Overall Survival

    The time from randomization to the death or to the latest date when participants are known to be alive. Overall survival was analyzed using Kaplan-Meier method; participants who were alive or lost to follow-up were censored at the latest date they were known to be alive.

    Time frame: From first dose of study drug up to end of study; median follow-up time was 19.1 months in the pomalidomide 0.5 mg arm and 17.6 months in the placebo arm.

  2. Duration of RBC-Transfusion Independence

    The duration of RBC-transfusion independence is the time from the date at which the first RBC-transfusion independence started to the date of another RBC-transfusion given at least 84 days after the time the transfusion independence started. The duration of the RBC-transfusion independence was analyzed using the Kaplan-Meier method. Data were censored at the end of the treatment phase for participants who had not received another RBC-transfusion after the start of transfusion independence by the end of treatment phase.

    Time frame: From first dose of study drug up to 28 days after last dose, as of the data cut-off date of 16 Jan 2013; median treatment duration was 23.6 weeks in the pomalidomide arm and 23.9 weeks in the placebo arm.

  3. Time to RBC-Transfusion Independence

    Time to response was measured from first dose of study drug to the start of the first response. The start date of the response was defined as one day after the last date of an RBC-transfusion for participants who received a RBC-transfusion after the first dose, and as the date of the first dose of study drug for participants who received no RBC-transfusions during the 84 days after the first dose of study drug.

    Time frame: 168 days

  4. Number of Participants With Treatment-emergent Adverse Events (TEAE)

    A TEAE is an adverse event (AE) that starts on or after the first dose of study drug. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE),Version 4.0 and according to the following scale: Grade 1 = Mild (transient or mild discomfort; no limitation in activity; no medical intervention/therapy required); Grade 2 = Moderate (mild to moderate limitation in activity, some assistance may be needed; minimal medical intervention/therapy required); Grade 3 = Severe (marked limitation in activity, assistance usually required; medical intervention/therapy required, hospitalization possible); Grade 4 = Life-threatening (extreme limitation in activity, significant assistance or medical intervention/therapy required, hospitalization or hospice care probable); Grade 5 = Death Drug-related (related) AEs are those suspected by the Investigator as being related to administration of study drug

    Time frame: From the first dose of study drug until 28 days after last dose; median treatment duration was 23.7 weeks in the pomalidomide arm, 23.9 weeks in the placebo arm, and 24.0 weeks in the China extension pomalidomide arm.

  5. Healthcare Resource Utilization

    Time frame: From first dose of study drug up to 28 days after last dose, as of the data cut-off date of 16 Jan 2013; median treatment duration was 23.6 weeks in the pomalidomide arm and 23.9 weeks in the placebo arm.

  6. Change From Baseline in EuroQoL-5D (EQ-5D) Health Index Score

    EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). For the health state profile participants rate their perceived health state today on 5 dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression on a Likert-type scale from 1 to 3, where 1 = "no problems," 2 = "some problems," and 3 = "extreme problems." The EQ-5D Health Utility Index (HUI) was generated from the five health state domain scores, and ranges from -0.594 (worst) and 1 (best) imaginable health state, with -0.594 representing an "unconscious" health state.

    Time frame: Baseline and Days 85 and 169

  7. Change From Baseline in EuroQoL-5D (EQ-5D) Visual Analog Scale

    EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). On the VAS the participant rates his/her health state on a line from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline and Days 85 and 169

  8. Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score

    The FACT-An is a 47-item, cancer-specific questionnaire consisting of a core 27-item general questionnaire measuring the four general domains of QoL (physical, social/family, emotional and functional well-being), and an additional 20-item anemia questionnaire (FACT-An Anemia subscale) that measures 13 fatigue-associated items (FACT-F Fatigue subscale) and seven non-fatigue-related items. Each item is scored using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). FACT-An total score is calculated by adding all the FACT-An subscales together. The total score ranges from 0-188 with higher scores representing better QOL.

    Time frame: Baseline and Days 85 and 169

07

Results

Posted Mar 14, 2014

Participant flow

Participants in the global study were enrolled at 72 clinical centers in 15 countries. In addition, the China-specific extension study enrolled participants with myeloproliferative neoplasm (MPN)-associated myelofibrosis and severe anemia not receiving red blood cell (RBC)-transfusions at 5 sites in China.

Participant flow — Overall Study
MilestonePomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mg
Started1688415
Received study drug1678315
Completed1688415
Not completed000

Outcome measures

PrimaryPercentage of Participants Who Achieved RBC-Transfusion Independence

RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval.

Time frame:
168 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved RBC-Transfusion Independence
percentage of participantsPomalidomide 0.5 mgPlacebo
Percentage of Participants Who Achieved RBC-Transfusion Independence17.3 (11.88 to 23.84)16.7 (9.42 to 26.38)
Statistical analysis
  • Pomalidomide 0.5 mg vs Placebo · Fisher Exact · p = 1.000
PrimaryChina Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days

A response in the China extension study was defined as an increase in hemoglobin ≥ 15 g/L above baseline value (in the absence of RBC transfusion) for ≥ 84 consecutive days.

Time frame:
From the first dose of study drug until treatment discontinuation; median treatment duration was 24.0 weeks.
Reported as:
Count of participants · Participants
China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days
ParticipantsChina Extension: Pomalidomide 0.5 mg
China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days1
SecondaryOverall Survival

The time from randomization to the death or to the latest date when participants are known to be alive. Overall survival was analyzed using Kaplan-Meier method; participants who were alive or lost to follow-up were censored at the latest date they were known to be alive.

Time frame:
From first dose of study drug up to end of study; median follow-up time was 19.1 months in the pomalidomide 0.5 mg arm and 17.6 months in the placebo arm.
Reported as:
Median · months
Overall Survival
monthsPomalidomide 0.5 mgPlacebo
Overall Survival24.2 (19.5 to 33.5)26.2 (18.0 to 32.6)
Statistical analysis
  • Pomalidomide 0.5 mg vs Placebo · Log Rank · p = 0.929
SecondaryDuration of RBC-Transfusion Independence

The duration of RBC-transfusion independence is the time from the date at which the first RBC-transfusion independence started to the date of another RBC-transfusion given at least 84 days after the time the transfusion independence started. The duration of the RBC-transfusion independence was analyzed using the Kaplan-Meier method. Data were censored at the end of the treatment phase for participants who had not received another RBC-transfusion after the start of transfusion independence by the end of treatment phase.

Time frame:
From first dose of study drug up to 28 days after last dose, as of the data cut-off date of 16 Jan 2013; median treatment duration was 23.6 weeks in the pomalidomide arm and 23.9 weeks in the placebo arm.
Reported as:
Median · months
Duration of RBC-Transfusion Independence
monthsPomalidomide 0.5 mgPlacebo
Duration of RBC-Transfusion IndependenceNA (4.8 to NA)5.8 (3.0 to NA)
SecondaryTime to RBC-Transfusion Independence

Time to response was measured from first dose of study drug to the start of the first response. The start date of the response was defined as one day after the last date of an RBC-transfusion for participants who received a RBC-transfusion after the first dose, and as the date of the first dose of study drug for participants who received no RBC-transfusions during the 84 days after the first dose of study drug.

Time frame:
168 days
Reported as:
Median · weeks
Time to RBC-Transfusion Independence
weeksPomalidomide 0.5 mgPlacebo
Time to RBC-Transfusion Independence6.9 (0.1 to 20.1)2.4 (0.1 to 15.4)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE)

A TEAE is an adverse event (AE) that starts on or after the first dose of study drug. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE),Version 4.0 and according to the following scale: Grade 1 = Mild (transient or mild discomfort; no limitation in activity; no medical intervention/therapy required); Grade 2 = Moderate (mild to moderate limitation in activity, some assistance may be needed; minimal medical intervention/therapy required); Grade 3 = Severe (marked limitation in activity, assistance usually required; medical intervention/therapy required, hospitalization possible); Grade 4 = Life-threatening (extreme limitation in activity, significant assistance or medical intervention/therapy required, hospitalization or hospice care probable); Grade 5 = Death Drug-related (related) AEs are those suspected by the Investigator as being related to administration of study drug

Time frame:
From the first dose of study drug until 28 days after last dose; median treatment duration was 23.7 weeks in the pomalidomide arm, 23.9 weeks in the placebo arm, and 24.0 weeks in the China extension pomalidomide arm.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE)
ParticipantsPomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mg
Any adverse event (AE)1648112
Adverse event suspected as related to study drug90323
Adverse event leading to dose interruption48172
Drug-related AE leading to dose interruption2661
AE leading to discontinuation of study drug53140
Related AE leading to study drug discontinuation2180
Grade 3/4 adverse event100444
Grade 3/4 AE related to study drug45130
Grade 3/4 AE leading to study drug discontinuation3390
Grade 3/4 AE leading to dose interruption36141
Grade 5 adverse event17100
Grade 5 AE related to study drug130
Serious adverse event (SAE)76290
SAE related to study drug2470
SAE leading to discontinuation of study drug3180
SAE leading to dose interruption2270
SecondaryHealthcare Resource Utilization
Time frame:
From first dose of study drug up to 28 days after last dose, as of the data cut-off date of 16 Jan 2013; median treatment duration was 23.6 weeks in the pomalidomide arm and 23.9 weeks in the placebo arm.

No measurements were reported for this outcome.

SecondaryChange From Baseline in EuroQoL-5D (EQ-5D) Health Index Score

EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). For the health state profile participants rate their perceived health state today on 5 dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression on a Likert-type scale from 1 to 3, where 1 = "no problems," 2 = "some problems," and 3 = "extreme problems." The EQ-5D Health Utility Index (HUI) was generated from the five health state domain scores, and ranges from -0.594 (worst) and 1 (best) imaginable health state, with -0.594 representing an "unconscious" health state.

Time frame:
Baseline and Days 85 and 169
Reported as:
Mean · score on a scale
Change From Baseline in EuroQoL-5D (EQ-5D) Health Index Score
score on a scalePomalidomide 0.5 mgPlacebo
Day 85-0.0385 ± 0.2480-0.0298 ± 0.2129
Day 169-0.0202 ± 0.16660.0766 ± 0.1546
SecondaryChange From Baseline in EuroQoL-5D (EQ-5D) Visual Analog Scale

EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). On the VAS the participant rates his/her health state on a line from 0 (worst imaginable health) to 100 (best imaginable health).

Time frame:
Baseline and Days 85 and 169
Reported as:
Mean · units on a scale
Change From Baseline in EuroQoL-5D (EQ-5D) Visual Analog Scale
units on a scalePomalidomide 0.5 mgPlacebo
Day 852.0 ± 20.78-1.4 ± 14.07
Day 1692.9 ± 22.850.3 ± 24.25
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score

The FACT-An is a 47-item, cancer-specific questionnaire consisting of a core 27-item general questionnaire measuring the four general domains of QoL (physical, social/family, emotional and functional well-being), and an additional 20-item anemia questionnaire (FACT-An Anemia subscale) that measures 13 fatigue-associated items (FACT-F Fatigue subscale) and seven non-fatigue-related items. Each item is scored using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). FACT-An total score is calculated by adding all the FACT-An subscales together. The total score ranges from 0-188 with higher scores representing better QOL.

Time frame:
Baseline and Days 85 and 169
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score
units on a scalePomalidomide 0.5 mgPlacebo
Day 85-2.1 ± 20.324.3 ± 18.73
Day 1696.2 ± 20.4911.9 ± 18.60

Adverse events

Collected over All-cause mortality data are reported from first dose of study drug up to end of study; maximum follow-up time was 85 months. Adverse events are reported from the first dose of study drug until 28 days after last dose; median treatment duration was 23.7 weeks in the pomalidomide arm, 23.9 weeks in the placebo arm, and 24.0 weeks in the China extension pomalidomide arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Global Study: Pomalidomide 0.5 mg115/167 (68.9%)76/167 (45.5%)155/167 (92.8%)
Global Study: Placebo54/83 (65.1%)29/83 (34.9%)76/83 (91.6%)
China Extension: Pomalidomide 0.5 mg8/15 (53.3%)0/15 (0%)12/15 (80%)
Most frequent serious events
Showing 10 of 119
Most frequent serious events
EventGlobal Study: Pomalidomide 0.5 mgGlobal Study: PlaceboChina Extension: Pomalidomide 0.5 mg
ANAEMIABlood and lymphatic system disorders10/1673/830/15
MYELOFIBROSISNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/1673/830/15
PNEUMONIAInfections and infestations6/1674/830/15
PYREXIAGeneral disorders5/1673/830/15
CARDIAC FAILURECardiac disorders5/1671/830/15
THROMBOCYTOPENIABlood and lymphatic system disorders3/1672/830/15
DIARRHOEAGastrointestinal disorders0/1672/830/15
MULTI-ORGAN FAILUREGeneral disorders2/1672/830/15
OEDEMA PERIPHERALGeneral disorders4/1670/830/15
FEBRILE NEUTROPENIABlood and lymphatic system disorders3/1671/830/15
Most frequent other events
Showing 10 of 47
Most frequent other events
EventGlobal Study: Pomalidomide 0.5 mgGlobal Study: PlaceboChina Extension: Pomalidomide 0.5 mg
OEDEMA PERIPHERALGeneral disorders53/16714/831/15
DIARRHOEAGastrointestinal disorders35/16717/832/15
FATIGUEGeneral disorders35/16717/833/15
NAUSEAGastrointestinal disorders21/16716/830/15
PYREXIAGeneral disorders30/1679/832/15
DYSPNOEARespiratory, thoracic and mediastinal disorders28/1678/831/15
NEUTROPENIABlood and lymphatic system disorders25/1674/830/15
THROMBOCYTOPENIABlood and lymphatic system disorders21/16712/831/15
DIZZINESSNervous system disorders17/16712/830/15
CONSTIPATIONGastrointestinal disorders24/1679/830/15

Baseline characteristics

Intent to Treat (ITT) population included all randomized (global study) or enrolled (China extension study) participants

Age, Continuous
Age, Continuous(years)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
Global study69.0 (40.0 to 90.0)69.0 (44.0 to 81.0)—69.0 (40.0 to 90.0)
China extension study——63.0 (41.0 to 76.0)63.0 (41.0 to 76.0)
Sex: Female, Male
Sex: Female, Male(Participants)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
Female4128675
Male127569192
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
Hispanic or Latino3104
Not Hispanic or Latino1447915238
Unknown or Not Reported214025
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
American Indian or Alaskan Native1001
Asian20111546
Black or African American2305
Native Hawaiian or Other Pacific Islanders1001
White122660188
Other3003
Missing194023
Baseline RBC Transfusion Burden
Baseline RBC Transfusion Burden(units per 28 days)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
Global study2.7 (1.3 to 13.3)2.8 (1.3 to 10.0)—2.7 (1.3 to 13.3)
China extension study——0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
0 (Fully active)5322580
1 (Restricted but ambulatory)85479141
2 (Ambulatory but unable to work)3015146
3 (Limited self-care)0000
4 (Completely disabled)0000
Disease Sub-type
Disease Sub-type(Participants)Pomalidomide 0.5 mgPlaceboChina Extension: Pomalidomide 0.5 mgTotal
Primary myelofibrosis1276510202
Post-polycythemia vera myelofibrosis178227
Post-essential thrombocythemia myelofibrosis2311337
Missing1001
08

Study locations

87 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • University of Florida Shands Cancer Center
    Gainesville, Florida 32610, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Mount Sinai School of Medicine Brookdale University Hospital
    Brooklyn, New York 11212, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Ruttenberg Treatment Center
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Medicine Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Avera Hematology and Transplant
    Sioux Falls, South Dakota 57105, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
  • Royal North Shore Hospital
    St. Leonards, New South Wales 2065, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Medizinische Universitatklinik Graz
    Graz, A-8036, Austria
  • Medizinische Universitat Innsbruck
    Innsbruck, A-6020, Austria
  • Medizinische Universitat Wien
    Vienna, A-1190, Austria
  • Algemeen Ziekenhuis Sint-Jan
    Brugge, 8000, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Universitaire Ziekenhuis Leuven Gathuisberg
    Leuven, 3000, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G lz2, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de L'Universite de Montreal
    Montreal,, Canada
  • Peking University People's Hospital
    Beijing, 100044, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Jiangsu Province Hospital
    Jiangsu, 210029, China
  • Shanghai Ruijin Hospital
    Shanghai, 200025, China
  • West China Hospital, Sichuan University
    Sichuan, 610041, China
  • Blood Disease Hospital Chinese Academy of Medical Sciences
    Tianjin, 300041, China
  • Hopital Albert Michallon
    La Tronche, 38043, France
  • Hopital Saint Vincent de Paul
    Lille, 59020, France
  • CHU Dupuytren
    Limoges, 87042, France
  • Hopital Saint-Louis
    Paris, 75475, France
  • CHRU - Hopital du Haut Leveque
    Pessac, 33604, France
  • Hopitaux Universitaires de Strasbourg, CHU Haute-Pierre
    Strasbourg, 67098, France
  • Hopital Purpan
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Universitatsklinikum Aachen
    Aachen, 52074, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Johannes Wesling Klinikum Minden
    Minden, 32429, Germany
  • Universitatsklinikum Ulm
    Ulm, 89081, Germany
  • Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari
    Bari, 70124, Italy
  • Ospedali Riuniti di Bergamo
    Bergamo, 24128, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50134, Italy
  • Azienda Ospedaliera Universitaria Federico II di Napoli
    Napoli, 80131, Italy
  • Azienda Ospedaliera San Luigi Gonzaga
    Orbassano, 10043, Italy
  • IRCCS Fondazione Policlinico San Matteo, Universita di Pavia, Centro per lo Studio della Mielofibrosi
    Pavia, 27100, Italy
  • IRCCS Fondazione Policlinico San Matteo, Universita di Pavia, Ematologia
    Pavia, 27100, Italy
  • Ospedale di Circolo e Fondazione Macchi Varese
    Varese, 21100, Italy
  • Juntendo University Hospital
    Bunkyou-ku, 113-8431, Japan
  • Kyushu University Hospital
    Fukuoka City, 812-8582, Japan
  • Tokai University Hospital
    Isehara City, 259-1193, Japan
  • Kyoto University Hospital
    Kyoto City, 606-8507, Japan
  • Nagasaki University Hospital
    Nagasaki City, 852-8501, Japan
  • Tokyo Medical University Hospital
    Shinjuku, 160-0023, Japan
  • VU University Medical Center
    Amsterdam, 1081 HV, Netherlands
  • Erasmus Medish Centrum
    Rotterdam, 3015 CE, Netherlands
  • University Medical Center Utrecht
    Utrecht, 3584 CX, Netherlands
  • Wojewodzki Szpital Specjalistyczny im. F.Chopina
    Rzeszow, 35-055, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 PAM
    Szczecin, 71-242, Poland
  • Centralny Szpital Kliniczny MSWiA
    Warsaw, 02-507, Poland
  • Russian Scientific Haematology Centre
    Moscow, 125167, Russian Federation
  • Federal State Institution Russian Scientific-research Institute of Hematology and Transfusiology of Federal Medical-Biological Agency of Russia
    Saint-Petersburg, 191024, Russian Federation
  • State Pavlov Medical University
    Saint-Petersburg, 196022, Russian Federation
  • Federal State Institution "Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies named after V.A. Almazov"
    Saint-Petersburg, 197341, Russian Federation
  • Hospital Clinic I Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Puerta De Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Hospital Clinico de Salamanca
    Salamanca, 37007, Spain
  • Hospital Clinico de Valencia
    Valencia, 46010, Spain
  • Skane University Hospital
    Lund, 22185, Sweden
  • Karolinska University Hospital Huddinge
    Stockholm, 14185, Sweden
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Beatson Oncology Centre
    Glasgow, G12 0YN, United Kingdom
  • John Radcliffe Hospital NHS Trust
    Headington, OX3 9DU, United Kingdom
  • St. Thomas Hospital
    London, SE1 9RT, United Kingdom
  • Hammersmith Hospital
    London, W12 ONN, United Kingdom
  • Freeman Hospital
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Royal Hallamshire Hospital
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Erratum In: Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. PubMed 27773929 ↗
  • Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012 Jan;87(1):66-8. doi: 10.1002/ajh.22233. Epub 2011 Nov 12. PubMed 22081489 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Jan 2013, 27 months.

Results were first posted in Mar 2014, 1 year 2 months after primary completion.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Aug 10, 2010
StartActual
Sep 8, 2010
Primary completionActual
Jan 1, 2013
CompletionActual
May 15, 2018
Results first posted
Mar 14, 2014
Last update
Jul 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01178281
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 10, 2010
Start date
Sep 8, 2010
Primary completion
Jan 1, 2013
Completion
May 15, 2018
Results posted
Mar 14, 2014
Last update
Jul 17, 2019

Study contacts

Robert Peter P Gale, MD, Ph.D.
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion